CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants ROCKVILLE, Md., Sept. 21, 2015 - CASI Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has entered into definitive agreements for a $25.1 million financing led by a China investment fund manager affiliated with the same management team of our current largest shareholder, IDG-Accel China Growth Fund III, L.P.